Advisor Group’s Oruka Therapeutics ORKA Stock Holding History

Advisor Group’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	5	–	–	﹤0.01%	5470
2019 Q3	$0	Hold	5	–	–	﹤0.01%	5453
2019 Q2	$0	Hold	5	–	–	﹤0.01%	5380
2019 Q1	$0	Hold	5	–	–	﹤0.01%	5354
2018 Q4	$0	Buy	+5	New	+$620	﹤0.01%	5263
2018 Q3	–	Hold	0	–	–	–	5244

Other funds holding ORKA

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisor Group's ORKA Position: Q4 2019 in Review

Advisor Group held its Oruka Therapeutics (ORKA) position steady in Q4 2019 at 5 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5470.

Advisor Group first reported a position in ORKA in Q4 2018 and has held it in 5 quarters since. 12 funds tracked by Wall St. Rank hold ORKA as of Q4 2019.

Advisor Group held 5 shares of Oruka Therapeutics worth $0 as of Q4 2019.
Advisor Group left its Oruka Therapeutics share count unchanged in Q4 2019.
Oruka Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5470 holding.
Advisor Group first reported a position in Oruka Therapeutics in Q4 2018 and has held it in 5 quarters since.
12 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.